Evidence map›Paper›PMID 25099132›Full record

ArticleJournal of the American Heart Association2014

Acrolein exposure is associated with increased cardiovascular disease risk.

Natasha DeJarnett, Daniel J Conklin, Daniel W Riggs, John A Myers, Timothy E O'Toole, Ihab Hamzeh, Stephen Wagner, Atul Chugh, Kenneth S Ramos, Sanjay Srivastava and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 4 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pulmonary effects of e-liquid flavors: a systematic review.Journal of toxicology and environmental health. Part B, Critical reviews · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. The Green Heart Project: objectives, design, and methods.American journal of epidemiology · 2026
    Article
  9. Use of Human Serum Albumin CysAntioxidants (Basel, Switzerland) · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. High-throughput UPLC-ESI/MSMS method for simultaneous measurement of the urinary metabolites of volatile organic compounds and tobacco alkaloids.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2025
    Article
  17. Article
  18. Review
  19. Review
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Natasha DeJarnettDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Department of Environmental and Occupational Health Sciences, University of Louisville, Louisville, KY (N.D.J., D.J.T., R.Y.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Daniel J ConklinDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Daniel W RiggsDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
John A MyersDepartment of Pediatrics, University of Louisville, Louisville, KY (J.A.M.).
Timothy E O'TooleDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Ihab HamzehBaylor College of Medicine, Houston, TX (I.H.).
Stephen WagnerInstitue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Atul ChughDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Kenneth S RamosDepartment of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY (K.S.R., A.B.).
Sanjay SrivastavaDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Deirdre HigdonInstitue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
David J TollerudDepartment of Environmental and Occupational Health Sciences, University of Louisville, Louisville, KY (N.D.J., D.J.T., R.Y.).
Andrew DeFilippisDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.) Department of Medicine, Johns Hopkins University, Baltimore, MD (A.D.F.).
Carrie BecherInstitue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Brad WyattDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
James McCrackenDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Wes AbplanalpDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Shesh N RaiDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Department of Bioinformatics and Biostatics, University of Louisville, Louisville, KY (S.N.R.) Biostatistics Shared Facility, JG Brown Cancer Center, University of Louisville, Louisville, KY (S.N.R.).
Tiffany CiszewskiDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Zhengzhi XieDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
Ray YeagerDepartment of Environmental and Occupational Health Sciences, University of Louisville, Louisville, KY (N.D.J., D.J.T., R.Y.).
Sumanth D PrabhuInstitue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.) Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL (S.D.P.).
Aruni BhatnagarDiabetes and Obesity Center, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., A.C., S.S., A.D.F., B.W., J.M.C., W.A., S.N.R., T.C., Z.X., A.B.) Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY (K.S.R., A.B.) Institue of Molecular Cardiology, University of Louisville, Louisville, KY (N.D.J., D.J.C., D.W.R., T.E.T., S.W., A.C., S.S., D.H., A.D.F., C.B., B.W., J.M.C., W.A., T.C., Z.X., S.D.P., A.B.).
University of Louisville · USBaylor College of Medicine · USUniversity of Alabama at Birmingham · US

Funding

Research Training and Education Core (Core D) P50HL120163 · NHLBI · AMERICAN HEART ASSOCIATION · PI O'TOOLE, TIMOTHY E · 2013 to 2017
$20.1M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Project 5 - Metabolomic Analysis of AtherothrombosisP20GM103492 · NIGMS · UNIVERSITY OF LOUISVILLE · PI JONES, STEVEN P · 2012 to 2017
$13.8M
Role of Platelet Activation and Vascular Pathology in Aldehyde ToxicityP01ES011860 · NIEHS · UNIVERSITY OF LOUISVILLE · PI BHATNAGAR, ARUNI BHATNAGAR · 2003 to 2007
$7.0M
Endothelial Progenitor Cells and Particulate Air PollutionR01ES019217 · NIEHS · UNIVERSITY OF LOUISVILLE · PI BHATNAGAR, ARUNI, O'TOOLE, TIMOTHY E · 2011 to 2022
$6.0M
Strategic Vision & Impact on Environmental HealthP30ES014443 · NIEHS · UNIVERSITY OF LOUISVILLE · PI PROUGH, RUSSELL ALLEN · 2007 to 2010
$4.4M
NHLBI NIH HHS HL120163NHLBI NIH HHS P50 HL120163NIEHS NIH HHS ES11860NIEHS NIH HHS ES19217NIEHS NIH HHS P01 ES011860NIEHS NIH HHS P30 ES014443NIEHS NIH HHS P30ES014443NIEHS NIH HHS R01 ES019217NIGMS NIH HHS GM103492NIGMS NIH HHS P20 GM103492
6 · The paper itself

Abstract

backgroundAcrolein is a reactive aldehyde present in high amounts in coal, wood, paper, and tobacco smoke. It is also generated endogenously by lipid peroxidation and the oxidation of amino acids by myeloperoxidase. In animals, acrolein exposure is associated with the suppression of circulating progenitor cells and increases in thrombosis and atherogenesis. The purpose of this study was to determine whether acrolein exposure in humans is also associated with increased cardiovascular disease (CVD) risk. METHODS AND

resultsAcrolein exposure was assessed in 211 participants of the Louisville Healthy Heart Study with moderate to high (CVD) risk by measuring the urinary levels of the major acrolein metabolite-3-hydroxypropylmercapturic acid (3-HPMA). Generalized linear models were used to assess the association between acrolein exposure and parameters of CVD risk, and adjusted for potential demographic confounders. Urinary 3-HPMA levels were higher in smokers than nonsmokers and were positively correlated with urinary cotinine levels. Urinary 3-HPMA levels were inversely related to levels of both early (AC133(+)) and late (AC133(-)) circulating angiogenic cells. In smokers as well as nonsmokers, 3-HPMA levels were positively associated with both increased levels of platelet-leukocyte aggregates and the Framingham Risk Score. No association was observed between 3-HPMA and plasma fibrinogen. Levels of C-reactive protein were associated with 3-HPMA levels in nonsmokers only.

conclusionsRegardless of its source, acrolein exposure is associated with platelet activation and suppression of circulating angiogenic cell levels, as well as increased CVD risk.

Indexed as

AcroleinAcetylcysteineAdultAgedBlood PlateletsCardiovascular DiseasesC-Reactive ProteinEnvironmental ExposureFemaleHumansKentuckyLeukocytesLinear ModelsMaleMiddle AgedPlatelet ActivationAcetylcysteineAcroleinC-Reactive ProteinS-(3-hydroxypropyl)cysteine N-acetateendotheliumepidemiologyinflammationrisk factorssmokingthrombosistobacco

Identifiers

PMID25099132
PMCPMC4310380
OpenAlexW2096220628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.